BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 36420774)

  • 21. [Prospect for chimeric antigen receptor-engineered T cell immunotherapy for solid tumors].
    Zhou SY; Shi YK
    Zhonghua Zhong Liu Za Zhi; 2018 Jul; 40(7):490-492. PubMed ID: 30060355
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Recent Advances in CAR-Based Solid Tumor Immunotherapy.
    Shin MH; Oh E; Kim Y; Nam DH; Jeon SY; Yu JH; Minn D
    Cells; 2023 Jun; 12(12):. PubMed ID: 37371075
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Engineered in vitro tumor models for cell-based immunotherapy.
    Ando Y; Mariano C; Shen K
    Acta Biomater; 2021 Sep; 132():345-359. PubMed ID: 33857692
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Understanding the immune landscape and tumor microenvironment of pancreatic cancer to improve immunotherapy.
    Torphy RJ; Schulick RD; Zhu Y
    Mol Carcinog; 2020 Jul; 59(7):775-782. PubMed ID: 32166821
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immunotherapy in hematologic malignancies.
    Kansara RR; Speziali C
    Curr Oncol; 2020 Apr; 27(Suppl 2):S124-S131. PubMed ID: 32368182
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The natural killer cell immunotherapy platform: An overview of the landscape of clinical trials in liquid and solid tumors.
    Piccinelli S; Romee R; Shapiro RM
    Semin Hematol; 2023 Jan; 60(1):42-51. PubMed ID: 37080710
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cancer immunotherapy: will expanding knowledge lead to success in pediatric oncology?
    Fry TJ; Lankester AC
    Pediatr Clin North Am; 2008 Feb; 55(1):147-67, xi. PubMed ID: 18242319
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Adoptive Cell Therapy in Treating Pediatric Solid Tumors.
    Tesfaye M; Savoldo B
    Curr Oncol Rep; 2018 Aug; 20(9):73. PubMed ID: 30069644
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Folate-targeted immunotherapies: Passive and active strategies for cancer.
    Farran B; Pavitra E; Kasa P; Peela S; Rama Raju GS; Nagaraju GP
    Cytokine Growth Factor Rev; 2019 Feb; 45():45-52. PubMed ID: 30770191
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immunotherapy for brain tumors: understanding early successes and limitations.
    Lieberman NAP; Vitanza NA; Crane CA
    Expert Rev Neurother; 2018 Mar; 18(3):251-259. PubMed ID: 29322843
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immunotherapy in kidney cancer: the past, present, and future.
    Hammers H
    Curr Opin Urol; 2016 Nov; 26(6):543-7. PubMed ID: 27533501
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Advances in Chimeric Antigen Receptor T-Cell Therapies for Solid Tumors.
    Baybutt TR; Flickinger JC; Caparosa EM; Snook AE
    Clin Pharmacol Ther; 2019 Jan; 105(1):71-78. PubMed ID: 30406956
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immunotherapy in Pediatric Solid Tumors-A Systematic Review.
    Marayati R; Quinn CH; Beierle EA
    Cancers (Basel); 2019 Dec; 11(12):. PubMed ID: 31847387
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pediatric brain tumors: the era of molecular diagnostics, targeted and immune-based therapeutics, and a focus on long term neurologic sequelae.
    Plant-Fox AS; O'Halloran K; Goldman S
    Curr Probl Cancer; 2021 Aug; 45(4):100777. PubMed ID: 34303558
    [TBL] [Abstract][Full Text] [Related]  

  • 35. New concepts in tumor antigens: their significance in future immunotherapies for tumors.
    Yang F; Yang XF
    Cell Mol Immunol; 2005 Oct; 2(5):331-41. PubMed ID: 16368059
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [New principles in tumor antigens and their significance in future immunotherapies for lymphomas and other malignancies--editorial].
    Ke XY; Wang J; Yang XF
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2006 Jun; 14(3):419-26. PubMed ID: 16800912
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pediatric Cancer Immunotherapy: Opportunities and Challenges.
    Wedekind MF; Denton NL; Chen CY; Cripe TP
    Paediatr Drugs; 2018 Oct; 20(5):395-408. PubMed ID: 29948928
    [TBL] [Abstract][Full Text] [Related]  

  • 38. T-cell-based immunotherapy of acute myeloid leukemia: current concepts and future developments.
    Daver N; Alotaibi AS; Bücklein V; Subklewe M
    Leukemia; 2021 Jul; 35(7):1843-1863. PubMed ID: 33953290
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Opportunities and challenges in the immunological therapy of pediatric malignancy: a concise snapshot.
    Ceppi F; Beck-Popovic M; Bourquin JP; Renella R
    Eur J Pediatr; 2017 Sep; 176(9):1163-1172. PubMed ID: 28803259
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immunotherapy in pediatric malignancies: current status and future perspectives.
    Capitini CM; Otto M; DeSantes KB; Sondel PM
    Future Oncol; 2014; 10(9):1659-78. PubMed ID: 25145434
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.